Online recorded patient reported outcome measures in the Severe Heterogeneous Asthma Research Collaboration Patient-centered (SHARP) registry could provide information for early assessment of response to biologics in patients with severe asthma

<fig><object-id>erj;66/suppl_69/PA473/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig> <bold>RATIONALE</bold> Patient reported outcome measures (PROs) are used for assessment of response to biological treatment (Khaleva et al, 2023). <bold>AIM</bold> To assess if the improvement of PRO data collected in SHARP registry at 3 months follow-up could predicted response to biologics. <bold>METODS and RESULTS</bold> We included 51 patients (29% female, mean age 53 (SD 15)) who started biologics 0-4 months before including to SHARP boa study and 112 patients (49% female, mean age 56 (SD 12)) who have biologics longer than 1 year. 51% (26 patients) have improvement in ACQ-6 already at 3-months, 15 (29%) of them have decreased ACQ-6>0,5 and 11 (22%) have ACQ-6<1.5 from start, without increase. This improvement remained at 6-months after start of biologics indicating a good response to biologics. ACQ-6 strongly correlated with SAQ-score (Fig 1). 78% patients treated with biologics longer than 1 years had good control over time of asthma according to ACQ-6 and are suggested to be in remission. <bold>CONCLUSION</bold> We suggest that prospective PROs data recording could be useful information for early assessment of response to biological treatment in patients in severe asthma. Long-term recording of PROs may also help to monitor remission, whereas lost asthma control indicates the need for a change in treatment.